Ocugen (OCGN) Non-Current Debt (2014 - 2026)
Ocugen (OCGN) reported Non-Current Debt of $24.2 million for Q1 2026, down 12.58% on a YoY basis from $27.7 million in Q1 2025, and down 12.17% quarter-over-quarter from $27.5 million in Q4 2025.
Ocugen (OCGN) Non-Current Debt (2014 - 2026) Analysis & Trends
Ocugen has reported Non-Current Debt for 13 years, with the latest figure at $24.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt fell 12.58% year-over-year to $24.2 million; the trailing twelve-month figure through Mar 2026 stood at $24.2 million (down 12.58% YoY), and the FY2025 full-year result was $27.5 million, up 0.72% from the prior year.
- Non-Current Debt for Q1 2026 stood at $24.2 million, down from $27.5 million in the prior quarter.
- The five-year high for Non-Current Debt was $28.4 million in Q3 2025, with the low at $1.1 million in Q1 2023.
- Historically, Non-Current Debt has averaged $10.7 million across 5 years, with a median of $2.3 million in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Debt plunged 38.88% — and 2025, when it jumped 1707.77%.
- Ocugen's Non-Current Debt stood at $2.3 million in 2022, then rose by 22.32% to $2.8 million in 2023, then surged by 876.61% to $27.3 million in 2024, then increased by 0.72% to $27.5 million in 2025, then decreased by 12.17% to $24.2 million in 2026.
- The last three Non-Current Debt figures came in at $24.2 million (Q1 2026), $27.5 million (Q4 2025), and $28.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | 24.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.19 Mn |
| Mar 31, 2026 | 24.19 Mn |
| Dec 31, 2025 | 27.54 Mn |
| Dec 31, 2025 | 27.54 Mn |
| Sep 30, 2025 | 28.40 Mn |
| Sep 30, 2025 | 28.40 Mn |
| Jun 30, 2025 | 28.03 Mn |
| Jun 30, 2025 | 28.03 Mn |
| Mar 31, 2025 | 27.67 Mn |
| Mar 31, 2025 | 27.67 Mn |
| Dec 31, 2024 | 27.35 Mn |
| Dec 31, 2024 | 27.35 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Dec 31, 2023 | 2.80 Mn |